Vascular Access Technologies Inc.
Safe, precise central venous access on first attempt
This article was originally published in Start Up
Central venous access continues to be linked to an abnormally high risk of serious and life-threatening complications. Unintended damage to major organs results from the “blind” placement of a hollow needle through the patient’s skin and into the target vein. Vascular Access Technologies Inc. hopes to reduce complications with SAFECVAD, a novel steerable catheter that uses the femoral vein as its point of entry. It is observed under fluoroscopy as it follows a simple guided path to the jugular or subclavian vein, where it makes a visible “inside-out” exit at the exact desired location for central line catheter placement.
You may also be interested in...
The latest accelerated approval withdrawals in the US are milestones for accountability in the program – most notably with the withdrawal of an antimicrobial with confirmatory studies more than a decade overdue.
Based on promising Phase II data, two companies in South Korea are moving ahead with late-stage development in the gout space, with JW Pharmaceutical getting approvals to begin a multinational Phase III trial for epaminurad, while LG Chem has recently submitted an application for a Phase III program with its contender tigulixostat.
Final guidance targets the ‘multiplicity problem.’ At about half the length of the 2017 draft, the final removes some sections, truncates other and drops several examples.